Drugs / EPCAM-targeted CAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02729493 | Nov 2015 → Nov 2019 | liver cancer | Sinobioway Cell Therapy Co., Ltd. | Unknown | No outcome recorded |
| — | NCT02725125 | Nov 2015 → Nov 2019 | gastric neoplasm | Sinobioway Cell Therapy Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPCAM-targeted CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02725125 ↗ |
| Action | Deplete | “the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body” NCT02725125 ↗ |
| Modality | Cell therapy | “infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor(CAR)” NCT02725125 ↗ |
| Target | EPCAM | “a chimeric antigen receptor(CAR)that will bind to tumour cells that express the EPCAM protein on the cell surface” NCT02729493 ↗ |